DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Celecoxib in Treating Patients With Bladder Cancer

Phase 2

Completed

Conditions: Recurrent Bladder Cancer

Interventions: Drug: placebo
Drug: celecoxib

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT00006124

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1

Terminated

Conditions: Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: gefitinib
Radiation: radiation therapy
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00033449

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Phase 3

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Rectal Cancer
Stage III Colon Cancer
Recurrent Colon Cancer
Stage IV Colon Cancer
Stage III Rectal Cancer
Stage IV Rectal Cancer

Interventions: Biological: bevacizumab
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: fluorouracil

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 880

Registration Number: NCT00025337

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Leukemia
Chronic Myeloproliferative Disorders

Interventions: Drug: tipifarnib

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00005967

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Adenocarcinoma
Stage III Uterine Corpus Cancer AJCC v7
ERBB2 Gene Amplification
Stage IV Uterine Corpus Cancer AJCC v7
Recurrent Uterine Corpus Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Trastuzumab

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00006089

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: ixabepilone

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00025155

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cavity Cancer
Malignant Mesothelioma
Pancreatic Cancer
Cervical Cancer
Ovarian Cancer
Fallopian Tube Cancer
Head and Neck Cancer
Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00006981

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

Phase 1

Completed

Conditions: Carcinoma of the Appendix
Colorectal Cancer
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019773

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00007956

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

Phase 3

Completed

Conditions: Tumors Metastatic to Brain

Interventions: Radiation: radiation therapy
Drug: thalidomide
Procedure: quality-of-life assessment

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 332

Registration Number: NCT00033254

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy